| Advances in the treatment of hepatitis C virus infection. | |
| | |
MedLine Citation:
|
PMID: 22538244 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Since 2007, the annual age-adjusted mortality rate in hepatitis C virus (HCV) infection in the United States has been greater than that in HIV disease, reflecting the continuing decline in HIV-related mortality and the continuing increase in HCV-related mortality. The approval of 2 new direct-acting antivirals within the past year, as well as the promise offered by numerous other direct-acting agents in development, provides hope that we will be able to markedly improve our ability to cure HCV disease. The addition of a protease inhibitor (PI) to what has been the standard HCV therapy of peginterferon alfa and ribavirin dramatically improves sustained virologic response rates in treatment-naive patients with genotype 1 infection. Similar results have been observed in some treatment-experienced patients in whom prior peginterferon alfa/ribavirin therapy has failed. The use of these new agents has also permitted response-guided therapy, wherein early sustained virologic response to treatment allows for a shortened treatment duration. However, these new PIs add cost and adverse effects to HCV therapy. Boceprevir is associated with increased risk of anemia and dysgeusia, and telaprevir is associated with increased risk of anemia and skin and gastrointestinal adverse effects. Early studies indicate that the addition of PIs results in high response rates in patients with HCV/HIV coinfection. Other studies suggest that combinations of PIs and other direct-acting antivirals may ultimately permit cure when used in interferon sparing regimens. This article summarizes a presentation by David L. Thomas, MD, MPH, at the IAS-USA live continuing medical education course held in New York City in October 2011. |
| | |
Authors:
|
David L Thomas |
Related Documents
:
|
22413854 - Simultaneous measurement of urinary albumin and total protein may facilitate decision-m... 22345024 - Hiv testing and care systems focused on sexually transmitted hiv in china. 23600184 - Criminal responsibility for the non-disclosure of hiv-positive status before sexual act... 22670654 - Prevention case management improves socioeconomic standing and reduces symptoms of psyc... 22128044 - Protease inhibitor-associated qt interval prolongation (december). 23576504 - Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolut... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Topics in antiviral medicine Volume: 20 ISSN: 2161-5853 ISO Abbreviation: Top Antivir Med Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-04-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101560274 Medline TA: Top Antivir Med Country: United States |
Other Details:
|
Languages: eng Pagination: 5-10 Citation Subset: IM |
Affiliation:
|
The Johns Hopkins University, Baltimore, MD, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vertical ZnO nanowire growth on metal substrates.
Next Document: Sexually transmitted infections and HIV: diagnosis and treatment.